150 related articles for article (PubMed ID: 33025549)
21. Nucleotide Excision Repair Capacity and XPC and XPD Gene Polymorphism Modulate Colorectal Cancer Risk.
Mucha B; Pytel D; Markiewicz L; Cuchra M; Szymczak I; Przybylowska-Sygut K; Dziki A; Majsterek I; Dziki L
Clin Colorectal Cancer; 2018 Jun; 17(2):e435-e441. PubMed ID: 29793654
[TBL] [Abstract][Full Text] [Related]
22. XPD Lys751Gln and Asp312Asn polymorphisms and susceptibility to skin cancer: a meta-analysis of 17 case-control studies.
Zhu HL; Bao JM; Lin PX; Li WX; Zou ZN; Huang YE; Chen Q; Shen H
Asian Pac J Cancer Prev; 2014; 15(16):6619-25. PubMed ID: 25169498
[TBL] [Abstract][Full Text] [Related]
23. The effect of XPD polymorphisms on digestive tract cancers risk: a meta-analysis.
Du H; Guo N; Shi B; Zhang Q; Chen Z; Lu K; Shu Y; Chen T; Zhu L
PLoS One; 2014; 9(5):e96301. PubMed ID: 24787743
[TBL] [Abstract][Full Text] [Related]
24. Association between XPD Lys751Gln polymorphism and risk of head and neck cancer: a meta-analysis.
Yuan H; Niu YM; Wang RX; Li HZ; Chen N
Genet Mol Res; 2011 Nov; 10(4):3356-64. PubMed ID: 22179996
[TBL] [Abstract][Full Text] [Related]
25. XPD Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility: a meta-analysis of case-control studies.
Yin QH; Liu C; Hu JB; Meng RR; Li L; Wang YJ
Asian Pac J Cancer Prev; 2013; 14(1):231-6. PubMed ID: 23534729
[TBL] [Abstract][Full Text] [Related]
26. Relationship between XPD Lys 751 Gln polymorphism and colorectal cancer risk: a case-control study in a population-based study.
Rezaei H; Motovali-Bashi M; Khodadad K; Elahi A; Emami H; Naddaffnia H
Gastroenterol Hepatol Bed Bench; 2013; 6(1):18-24. PubMed ID: 24834240
[TBL] [Abstract][Full Text] [Related]
27. Lack of association between the XPD Lys751Gln polymorphism and colorectal cancer risk: a meta-analysis.
Zhang T; Zhang DM; Zhao D; Hou XM; Ma SC; Liu XJ
Onco Targets Ther; 2014; 7():1255-60. PubMed ID: 25050067
[TBL] [Abstract][Full Text] [Related]
28. XPD Lys751Gln polymorphisms and the risk of esophageal cancer: an updated meta-analysis.
Guo XF; Wang J; Lei XF; Zeng YP; Dong WG
Intern Med; 2015; 54(3):251-9. PubMed ID: 25748732
[TBL] [Abstract][Full Text] [Related]
29. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
[TBL] [Abstract][Full Text] [Related]
30. No association between XRCC3 Thr241Met and XPD Lys751Gln polymorphisms and the risk of colorectal cancer in West Algerian population: a case-control study.
Moghtit FZ; Aberkane MS; Le Morvan V; Louhibi L; Bellot R; Bousahba A; Megaiz A; Fodil M; Mediene-Benchekor S; Zemani-Fodil F; Boudjema A; Robert J; Saidi-Mehtar N
Med Oncol; 2014 May; 31(5):942. PubMed ID: 24687779
[TBL] [Abstract][Full Text] [Related]
31. Association between the XPD/ERCC2 Lys751Gln polymorphism and risk of cancer: evidence from 224 case-control studies.
Wu KG; He XF; Li YH; Xie WB; Huang X
Tumour Biol; 2014 Nov; 35(11):11243-59. PubMed ID: 25113251
[TBL] [Abstract][Full Text] [Related]
32. Association between XPD Lys751Gln polymorphism and bladder cancer susceptibility: an updated and cumulative meta-analysis based on 6,836 cases and 8,251 controls.
Li S; Zeng XT; Ruan XL; Liu TZ; Wang XH
Mol Biol Rep; 2014 Jun; 41(6):3621-9. PubMed ID: 24510389
[TBL] [Abstract][Full Text] [Related]
33. Significant association of XPD Asp312Asn polymorphism with breast cancer in Taiwanese patients.
Wang HC; Liu CS; Wang CH; Tsai RY; Tsai CW; Wang RF; Chang CH; Chen YS; Chiu CF; Bau DT; Huang CY
Chin J Physiol; 2010 Apr; 53(2):130-5. PubMed ID: 21793320
[TBL] [Abstract][Full Text] [Related]
34. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
[TBL] [Abstract][Full Text] [Related]
35. XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk.
Long XD; Ma Y; Zhou YF; Yao JG; Ban FZ; Huang YZ; Huang BC
BMC Cancer; 2009 Nov; 9():400. PubMed ID: 19919686
[TBL] [Abstract][Full Text] [Related]
36. XRCC1 and XPD genetic polymorphisms and susceptibility to age-related cataract: a meta-analysis.
Chi XX; Liu YY; Shi SN; Cong Z; Liang YQ; Zhang HJ
Mol Vis; 2015; 21():335-46. PubMed ID: 25873778
[TBL] [Abstract][Full Text] [Related]
37. [Polymorphism Lys751Gln of XPD gene and breast cancer risk in women].
Romanowicz-Makowska H; Smolarz B
Pol Merkur Lekarski; 2007 Aug; 23(134):107-9. PubMed ID: 18044339
[TBL] [Abstract][Full Text] [Related]
38. Impact of polymorphisms in DNA repair genes XPD, hOGG1 and XRCC4 on colorectal cancer risk in a Chinese Han Population.
Jin D; Zhang M; Hua H
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30429230
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.
Zhou JY; He LW; Liu J; Yu HL; Wei M; Ma WL; Shi R
Asian Pac J Cancer Prev; 2014; 15(21):9347-53. PubMed ID: 25422223
[TBL] [Abstract][Full Text] [Related]
40. DNA repair genes XPD and XRCC1 polymorphisms and risk of end-stage renal disease in Egyptian population.
Radwan WM; Elbarbary HS; Alsheikh NM
Ren Fail; 2015 Feb; 37(1):122-8. PubMed ID: 25310768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]